21 May 2009
Inflammatory markers (CRP, fibrinogen) in lung transplant recipients during cellular rejection
S Zeglen, J Wojarski, E Wozniak-Grygiel, R Buldak, J Nozynski, E Herczakowska, H Czarnecka, E Kucewicz-CzechAnn Transplant 2009; 14(1): 61-61 :: ID: 880426
Abstract
Background: Despite new immunosuppression protocols, cellular rejection has still an impact on survival after lung transplantation (LTx). The aim of the study was to analyse unspecific inflammatory markers like C-reactive protein (CRP) and fibrinogen in the context of cellular rejection.
Material/Methods: The study group included 7 LTx patients (2 women and 5 men, mean age 43.6±12.1 yr, BMI 21.0±7.1) at rejection periods (n=10) before and after methylprednisolonum administration (group A and B, respectively). The control group (group C) included 10 lung transplant recipients (3 women and 7 men, mean age 46.6±14.5 yr, BMI 18.2±3.0) at clinically stable period. Serum CRP levels were measured using a commercially available kit with the turbidimetric method and fibrinogen levels were measured by routine Clauss method.
Results: Intriguingly, no significant differences in average CRP values between analyzed groups were found (average CRP value of group C, A and B was 40.5±42.4, 42.3±52.0, 32.8±28.5; respectively). Significantly increased average fibrinogen value in group B was revealed when compared to group C (662.3±27.8 vs. 490.0±128.3, p<0.05; respectively).
Conclusions: Non-invasive diagnosis of acute cellular rejection in lung transplantation recipients is extremely difficult. Higher fibrinogen concentrations might be associated with increased risk of rejection.
Keywords: Lung Transplantation
In Press
Original article
Effect of Medical Accessibility on Long-Term Survival in Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.944839
Original article
Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-UpAnn Transplant In Press; DOI: 10.12659/AOT.946088
Most Viewed Current Articles
05 Apr 2022 : Original article 13,221
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,677
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,822
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,535
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860